Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

NCT04358614 is registered in ClinicalTrials.gov with Fabrizio Cantini as lead sponsor.

NCT NCT04358614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04358614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact
Lead sponsor
Fabrizio Cantini
Phase
Phase 2/3
Overall status
Completed
Start date
March 16, 2020
Completion date
April 7, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid, pneumonia